THE MOST FAVORED NATIONS MODEL INTERIM FINAL RULE IS FATALLY FLAWED AND MUST BE RESCINDED—YET THE PROBLEM IT ADDRESSES DEMANDS A SOLUTION

por Rubinstein, Elan
Publicado 2021

Grim Provider and Supplier Gross Margins of 1.8%-3.7% if CMS-1670-P Is Finalized As Proposed

por Rubinstein, Elan
Publicado 2016

Timeline and Potential Impact of CMS's Drug Competitive Acquisition Program (CAP)

por Rubinstein, Elan
Publicado 2006

How Much Spread in AWP Pricing Is Unlawful?

por Rubinstein, Elan, Curtiss, Frederic R.
Publicado 2007

Community Pharmacy and Mail Order Cost and Utilization for 90-Day Maintenance Medication Prescriptions

por Khandelwal, Nikhil, Duncan, Ian, Rubinstein, Elan, Ahmed, Tamim, Pegus, Cheryl
Publicado 2012

Evaluation of Increased Adherence and Cost Savings of an Employer Value-Based Benefits Program Targeting Generic Antihyperlipidemic and Antidiabetic Medications

por Clark, Bobby, DuChane, Janeen, Hou, John, Rubinstein, Elan, McMurray, Jennifer, Duncan, Ian
Publicado 2014